2/18/2025
Patient Case Story: PH
Short Excerpt: Diagnosed in 2021 with Stage IV esophageal adenocarcinoma with liver and lung metastases and a grim prognosis, PH combined aggressive standard therapies with a structured regimen of repurposed medications, mistletoe, targeted supplements, and disciplined dietary changes. Now years out with no evidence of disease, he believes “throwing everything you can at the cancer” and pursuing integrative, research-driven care played a key role in his exceptional outcome.
Patient Profile
- Age: 61 years
- Gender: Male
- Diagnosis: Stage IV esophageal adenocarcinoma with metastasis to liver/lung
- Date of Diagnosis: January 2021
- Current Status: No evidence of disease (NED) since December 2021
Clinical Course
PH initially presented with dysphagia (difficulty swallowing) and chest pain. His medical history included Barrett’s esophagus and a hiatal hernia, both known risk factors for esophageal adenocarcinoma. Staging revealed metastatic disease (T4N1M1), with a prognosis of 9–14 months.
Treatment Approach
Standard of Care (SOC) Therapies (March–December 2021)
- Surgical ablation.
- Chemotherapy: FOLFOX regimen (folinic acid, fluorouracil, oxaliplatin).
- Immunotherapy: Pembrolizumab (Keytruda), a PD-1 inhibitor.
Repurposed Medications Started 3/2021
- Fenbendazole (anthelmintic): Initiated immediately post-diagnosis. Started 2/2021
- Metformin (antidiabetic)
- Atorvastatin (lipid-lowering)
- Doxycycline (antibiotic)
- Mebendazole (anthelmintic)
- Ivermectin (antiparasitic)
Adjuvant Therapies
- Diet: Primarily plant-based, organic, no processed foods, no sugar.
- Supplements: Vitamin D/K, omega-3, melatonin, digestive enzymes, berberine, loratadine, and low-dose aspirin.
- Mistletoe Infusion therapy: used concurrently during chemotherapy and immunotherapy.
Outcome
PH achieved NED by December 2021, with restored swallowing function and sustained energy levels. He remains disease-free as of April 2025, exceeding typical survival expectations for stage IV esophageal cancer, where 5-year survival rates are approximately 5%. PH continues to take the repurposed medication and supplement protocol. He still pays attention to his diet and nutrition, but does allow occasional “cheat days”.
Survival Rates and Prognostic Factors
Stage IV esophageal cancer carries a median survival of 6–8 months, with 5-year survival rates of 5–7%, even with aggressive treatment. Factors linked to poorer outcomes include visceral metastasis (e.g., liver/lung involvement), anemia, and advanced T-stage. PH’s case defied these predictors, potentially due to a combination of SOC therapies, repurposed drugs, and lifestyle modifications.
Role of Repurposed Medications in Esophageal Cancer
While PH’s regimen is unique, emerging research supports investigating repurposed drugs for oncology:
- Metformin: Linked to reduced cancer progression via AMPK/mTOR pathway modulation.
- Atorvastatin: Exhibits antiproliferative effects through cholesterol pathway inhibition.
- Doxycycline: Targets mitochondrial function and matrix metalloproteinases in tumor microenvironments.
- Anthelmintics Fenbendazole/Mebendazole: Disrupt microtubule assembly, with preclinical activity against chemotherapy-resistant cells.
PH’s protocol aligns with drug-repurposing strategies that prioritize cost-effectiveness and safety.
Conclusion
PH’s case underscores the potential of integrating repurposed medications with standard therapies in managing advanced esophageal cancer. Although individual experiences vary and robust clinical trials are needed to confirm efficacy, PH’s positive response may indicate a tumor biology that is particularly sensitive to multimodal intervention.
Patient Advice – PH emphasizes aggressive, holistic intervention: “Throw everything you can at the cancer.” He encourages other patients to seek integrative care in addition to working with a traditional oncologist. His approach of combining SOC, repurposed drugs, and dietary rigor exemplifies patient-driven innovation in oncology.
This case illustrates the complex interplay of conventional and experimental therapies in advanced cancer. PH’s outcome is exceptional, highlighting the importance of personalized treatment strategies and the need for further research into the efficacy of repurposed medications.
References
- https://pubmed.ncbi.nlm.nih.gov/27623270/
- https://journals.lww.com/md-journal/fulltext/2020/03200/analysis_on_plausible_factors_related_to_the.1.aspx
- https://pubmed.ncbi.nlm.nih.gov/38662169/
- https://pubmed.ncbi.nlm.nih.gov/36618074/
- https://www.nature.com/articles/s41392-024-01808-1
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6610246/
- https://pubmed.ncbi.nlm.nih.gov/36010949/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7141161/
- https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e24104
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5723120/
